^
    16d
    Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer. (PubMed, J Thorac Oncol)
    MTAP dels frequently co-occur with oncogenic driver alterations and can develop at time of osimertinib resistance. A patient with oncogenic driver-positive, MTAP-del NSCLC had a partial response to PRMT5 inhibitor treatment. This work could inform future trials of PRMT5 and MAT2A inhibitors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • MAT2A (Methionine Adenosyltransferase 2A)
    |
    EGFR mutation • CDKN2A deletion • MTAP deletion
    |
    MSK-IMPACT
    |
    Tagrisso (osimertinib) • BMS‐986504
    18d
    A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BMS‐986504
    24d
    CA240-0007: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (clinicaltrials.gov)
    P1, N=336, Recruiting, Bristol-Myers Squibb | Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    BMS‐986504
    27d
    PRIME: Clinical Trial to investigate the feasibility, safety, and tolerability of BMS-986504 in patients with recurrent MTAP-deleted Glioblastoma (ACTRN12625001238460)
    P2, N=10, Not yet recruiting, Peter MacCallum Cancer Centre
    New P2 trial
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • MTAP (Methylthioadenosine Phosphorylase)
    |
    BMS‐986504
    3ms
    A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (clinicaltrials.gov)
    P2/3, N=470, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • BMS‐986504
    3ms
    MountainTAP-29: A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (clinicaltrials.gov)
    P2/3, N=590, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • BMS‐986504
    4ms
    A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Bristol-Myers Squibb
    New P1 trial
    |
    BMS‐986504
    4ms
    A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (clinicaltrials.gov)
    P2/3, N=470, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    gemcitabine • albumin-bound paclitaxel • BMS‐986504
    5ms
    Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. (PubMed, Cancer Res)
    While PRMT5 and KRAS regulated distinct transcriptomes, they converged on pathways governing cancer cell growth and expression of PDAC-essential genes. These findings provide rationale for combined inhibition of PRMT5 and KRAS in MTAP-deleted/KRAS-mutant PDAC.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MTAP (Methylthioadenosine Phosphorylase)
    |
    KRAS mutation • KRAS G12C • MTAP deletion
    |
    BMS‐986504
    5ms
    MountainTAP-29: A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (clinicaltrials.gov)
    P2/3, N=590, Not yet recruiting, Bristol-Myers Squibb
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • BMS‐986504
    7ms
    A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (clinicaltrials.gov)
    P2, N=130, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BMS‐986504
    7ms
    CA240-0007: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion (clinicaltrials.gov)
    P1, N=320, Recruiting, Bristol-Myers Squibb | Phase classification: P1/2 --> P1 | N=580 --> 320
    Phase classification • Enrollment change
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    BMS‐986504